Publication:
Acetogenins Exhibit Potential Bcl-xl Inhibitor For The Induction Of Apoptosis In The Molecular Docking Study

Simple item page
dc.contributor.authorNoraziah Nordinen_US
dc.contributor.authorKaynat Khimanien_US
dc.contributor.authorMohd Faiz Abd Ghanien_US
dc.date.accessioned2024-05-28T03:43:11Z
dc.date.available2024-05-28T03:43:11Z
dc.date.issued2021-02-04
dc.date.submitted2022-2-10
dc.description.abstractAnti-apoptotic protein BCL-XL plays a vital role in tumorigenesis and cancer chemotherapy resistance, resulting in a good target for cancer treatment. Understanding the function of BCL-XL has driven the progression of a new class of cancer drugs that can mimic its natural inhibitors, BH3-only proteins, to trigger apoptosis. This mimicking is initiated through acetogenins due to their excellent biological properties. Acetogenins, which can be isolated from Annonaceae plants, have a unique structure along with several oxygenated functionalities. Objective: Based on their biological capability, various acetogenins were studied in the present study and compared alongside ABT-737 on molecular docking. Methods: The docking simulation of acetogenins was performed using AutoDock Vina software. Results: Our findings have shown eleven acetogenins-BCL-XL protein complex, namely, muricin B (2), muricin F (4), muricin H (6), muricin I (7), xylomaticin (9), annomontacin (12), annonacin (14), squamocin (15), squamostatin A (16), bullatacin (20) and annoreticulin (21) exhibited strong binding affinities lower than – 10.4 kcalmol-1 as compared to ABT-373-BCL-XL complex. Six hydrogen bonds along with hydrophobic interaction were detected on the complex of BCL-XL with muricin B (2), muricin G (5), corossolone (11), and isoannonacin-10-one A (18). Conclusion: These findings indicated that some acetogenins could represent a new potential BCLXL inhibitor that could mimic the BH3-only protein for the induction of apoptosis in cancer chemotherapy.en_US
dc.identifier.citationNordin Noraziah, Khimani Kaynat and Abd Ghani Faiz Mohd , Acetogenins Exhibit Potential BCL-XL Inhibitor for the Induction of Apoptosis in the Molecular Docking Study, Current Drug Discovery Technologies 2021; 18(6) : e010921191171 . https://dx.doi.org/10.2174/1570163818666210204202426en_US
dc.identifier.doi10.2174/1570163818666210204202426
dc.identifier.epage11
dc.identifier.issn1570-1638
dc.identifier.issn1875-6220
dc.identifier.issue6
dc.identifier.other2169-22
dc.identifier.spage1
dc.identifier.urihttps://oarep.usim.edu.my/handle/123456789/4979
dc.identifier.volume18
dc.language.isoenen_US
dc.publisherBentham Science Publishersen_US
dc.relation.ispartofCurrent Drug Discovery Technologiesen_US
dc.subjectBCL-XL protein, acetogenins, docking, AutoDock vina, apoptosis, cancer chemotherapy.en_US
dc.titleAcetogenins Exhibit Potential Bcl-xl Inhibitor For The Induction Of Apoptosis In The Molecular Docking Studyen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Collections

Other Publications